Dataset describing the development, optimization and application of SRM/MRM based targeted proteomics strategy for quantification of potential biomarkers of EGFR TKI sensitivity
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Date
2018Journal
Data in BriefPublisher
Elsevier Inc.Type
Article
Metadata
Show full item recordAbstract
The data presented here describes the use of targeted proteomic assays to quantify potential biomarkers of Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) sensitivity in lung adenocarcinoma and is related to the research article: "Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma" [1]. This article describes the data associated with liquid chromatography coupled to multiple reaction monitoring (LC-MRM) method development which includes selection of an optimal transition list, retention time prediction and building of reverse calibration curves. Sample preparation and optimization which includes phosphotyrosine peptide enrichment via a combination of pan-phosphotyrosine antibodies is described. The dataset also consists of figures, tables and Excel files describing the quantitative results of testing these optimized methods in two lung adenocarcinoma cell lines with EGFR mutations. Copyright 2018Sponsors
This research was supported by the Intramural Research Program of the NIH , (ZIABC011410) Center for Cancer Research, National Cancer Institute (U.G.). Transparency documentIdentifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047458198&doi=10.1016%2fj.dib.2018.04.086&partnerID=40&md5=136e0a9569c393436fc99ad4383b623f; http://hdl.handle.net/10713/9149ae974a485f413a2113503eed53cd6c53
10.1016/j.dib.2018.04.086